Brad Stanfield on low-dose tirzepatide drstanfield.com, May 2026 SELECT trial semaglutide CV outcomes, NEJM, 2023 FLOW trial semaglutide kidney outcomes, NEJM, 2024 SURPASS-CVOT tirzepatide vs
The rising number of claims reflects increasing awareness among users who have experienced painful and debilitating side effects
Patients who were already low before their bariatric procedure are significantly more likely to be deficient at medium-term follow-up (7)
Analysis of a simulation model to estimate long-term outcomes in patients with nonalcoholic fatty liver disease
February 2, 2026: FDA Posts Updated Safety Label for Mounjaro On January 20, 2026, the FDA posted an updated safety/warning label with new patient information for those taking Mounjaro (tirzepatide)
&srotate=0)
Red flag symptoms requiring urgent medical attention include: Severe, persistent abdominal pain , particularly in the upper abdomen or epigastric region, which could indicate pancreatitis (a rare but serious adverse effect of GLP-1 therapy) Difficulty swallowing (dysphagia) or painful swallowing (odynophagia) Unintentional weight loss beyond expected therapeutic effects Persistent vomiting that prevents adequate oral intake or medication administration Right upper quadrant pain, fever, or yellowing of skin/eyes , which could indicate gallbladder disease (a known risk with weight loss on GLP-1 therapies) Symptoms of gastroparesis such as early satiety, postprandial fullness, or vomiting undigested food Call 911 or seek emergency care immediately for: Severe chest pain that could represent cardiac pathology rather than reflux Evidence of gastrointestinal bleeding , including black, tarry stools or vomiting blood or coffee-ground material If you suspect pancreatitis (persistent severe abdominal pain, sometimes radiating to the back, with or without nausea/vomiting), stop taking the GLP-1 medication immediately and seek urgent medical care, as directed in FDA prescribing information
